Juan Casado Flores-rekin lankidetzan egindako argitalpenak (7)

2019

  1. Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study

    Vaccine, Vol. 37, Núm. 16, pp. 2200-2207

2017

  1. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015

    PLoS ONE, Vol. 12, Núm. 2

  2. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children

    Vaccine, Vol. 35, Núm. 35, pp. 4646-4651

2013

  1. Expansion of serotype coverage in the universal pediatric vaccination calendar: Short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain

    Clinical and Vaccine Immunology, Vol. 20, Núm. 10, pp. 1524-1530

  2. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011

    Pediatric Infectious Disease Journal

2011

  1. Laboratory-based, 2-year surveillance of pediatric parapneumonic pneumococcal empyema following heptavalent pneumococcal conjugate vaccine universal vaccination in madrid

    Pediatric Infectious Disease Journal, Vol. 30, Núm. 6, pp. 471-474

  2. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar

    Clinical and Vaccine Immunology, Vol. 18, Núm. 1, pp. 89-94